# DeepSeek V4.1 Flash / inf-k01

Original final answer, shared by both scoring rounds.

**Bottom line / next action**  
From E1 alone, the defensible conclusion is only: **a locus containing G and H is associated with the trait**. Neither the **causal variant** nor the **effector gene** is identified. G is a weak positional candidate because the lead noncoding SNP is near it; H is equally inside the linked interval. The recommended next action is: (1) LD-aware fine-mapping in an ancestry-matched sample, (2) colocalization with trait-relevant molecular QTLs, and (3) allele-specific and gene-level functional perturbation. Until those are done, do not nominate a causal variant or effector gene.

---

### Evidence-to-inference-to-conclusion chain for E1

| Evidence | Inference | Conclusion / limit |
|---|---|---|
| E1: well-controlled GWAS identifies a lead noncoding SNP near G | The locus is statistically associated with the trait | Association is locus-level, not variant- or gene-level |
| E1: several linked variants span G and H | The associated signal is embedded in a linked/LD region containing multiple correlated variants across both genes | Any linked variant could be causal; G and H both remain candidates |
| E1: no functional or colocalization data supplied | There is no molecular evidence linking the locus to G or H | No effector gene can be inferred; no mechanism can be claimed |

Thus the full chain is: **GWAS association → linked/LD region → candidate variants and genes → [missing fine-mapping] → [missing colocalization] → [missing functional perturbation] → causal variant and effector gene**. The chain is broken after the first step in E1.

---

### Distinguishing the steps

**1. GWAS association**  
A well-controlled GWAS establishes a statistical relationship between genotype at the locus and the trait. It can identify a lead SNP and a genomic region. It **cannot** establish which variant is causal, which gene is affected, the direction of effect, or the mechanism. In E1, the lead SNP is noncoding and near G, but proximity is not causality.

**2. Linkage / LD**  
“Linked variants” here means variants in linkage disequilibrium: alleles correlated in the population because of physical proximity and shared ancestry. Linkage/LD defines a region and a set of correlated candidate variants. It can show that the lead SNP is a tag for other variants. It **cannot** distinguish causal from passenger variants, and it **cannot** assign an effector gene. In E1, because linked variants span G and H, both genes sit inside the same LD neighborhood. The lead SNP’s proximity to G gives G a slight positional prior, but H cannot be excluded. A noncoding variant could regulate G, H, both, or a distant gene through 3D contacts.

**3. Fine mapping**  
Fine mapping uses dense genotype data and LD structure to statistically resolve an association signal into one or more **credible sets**—sets of variants likely to contain the causal variant(s) at a chosen coverage, e.g. 95%. Methods include conditional analysis, SuSiE, FINEMAP, and CAVIAR. Fine mapping can narrow the candidate set and detect multiple independent signals. It **cannot prove causality**. Its credible set depends on assumptions: a single causal variant per signal, accurate ancestry-matched LD reference, good imputation, sufficient sample size, and correct phenotype. In E1, no fine-mapping data are supplied. “Several linked variants” is not a credible set; it is simply an LD region.

**4. Colocalization**  
Colocalization tests whether a GWAS signal and a molecular QTL—such as an eQTL or sQTL—share the same causal variant in a region. Methods include coloc, eCAVIAR, SMR/HEIDI, and SharePro. If the trait signal colocalizes with an eQTL for G, that strengthens G as the effector gene; if it colocalizes with an eQTL for H, it strengthens H. Colocalization can also suggest mechanism: expression, splicing, chromatin, or protein level. It **cannot prove causality**. It is tissue- and cell-type-dependent, power-limited, and can be confounded by two distinct causal variants in LD. Absence of colocalization does **not** exclude a gene, because the relevant QTL may not have been measured in the right tissue, time, or condition. In E1, no colocalization data are supplied, so neither G nor H has molecular support.

**5. Functional perturbation**  
Functional perturbation experimentally manipulates the candidate variant or gene. Variant-level assays include MPRA/reporter assays, CRISPR base editing of the SNP, allele-specific CRISPRi/CRISPRa, and saturation genome editing. Gene-level assays include CRISPRi/CRISPRa, knockout, RNAi, overexpression, and Perturb-seq. Chromatin conformation methods such as Hi-C, promoter capture, or 3C can connect a regulatory element to a promoter. Functional perturbation can establish a causal effect of a specific variant on a molecular phenotype, or of a gene on a cellular/trait-relevant phenotype. It **cannot alone prove human organism-level causality** without model validity, replication, and appropriate tissue/dosage/timing. Critically, gene perturbation and variant perturbation answer different questions: showing that knocking down H changes a phenotype does not prove that the GWAS variant acts through H. One needs the variant to alter H (or G) in an allele-specific way and for that molecular change to mediate the trait-relevant phenotype.

---

### What would change the conclusion

- If fine mapping yields a credible set that excludes H and contains a variant in a G regulatory element, G becomes the stronger candidate.
- If an H eQTL/sQTL colocalizes with the trait signal, H becomes the stronger candidate.
- If base editing of the candidate SNP changes G expression and a trait-relevant cellular phenotype, the variant→G→phenotype chain is supported.
- If CRISPRi of H changes the phenotype but the variant does not affect H, H may be a pathway gene but not the GWAS effector gene.
- If both G and H show colocalization or perturbation effects, the locus may have multiple effector genes, shared regulatory architecture, or indirect effects.
- If no colocalization is found, this is not exclusion; functional work in the right cell type is still needed.

---

### Assumptions and unreported parameters

E1 does not report sample size, ancestry, imputation quality, LD reference panel, credible set coverage, number of independent signals, effect sizes, tissue/cell type for QTLs, or any functional assay details. Because all figures are synthetic teaching materials and no validation data are supplied, no quantitative or mechanistic claim can be made. The correct interpretation of E1 is therefore: **a well-controlled GWAS association at a locus spanning G and H, with no resolution of the causal variant or effector gene**.
